Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial

Summary
Company plans to meet with the FDA and is preparing a biologics license application for the first half of 2027
Description from Quartz.
Who is covering this
-
Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial
Company plans to meet with the FDA and is preparing a biologics license application for the first half of 2027






Comments
Comments need JavaScript.